The Max Foundation’s 2019 Annual Report is Now Live

The Max Foundation’s 2019 Annual Report is Now Live

We are pleased to announce the publication of The Max Foundation’s 2019 Annual Report, showcasing the variety of achievements made possible with the support of our dedicated donors, partners, and global team.

Read the 2019 Annual Report

Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.

These new frontiers include our program’s expansion into Mozambique, where chronic myeloid leukemia (CML) patients gained access to lifesaving treatment for the first time. We also grew our access to diagnostics initiatives that allowed patients to have access to affordable and local molecular tests. And through our patient services, we connected with thousands of patients and their caregivers worldwide through one-on-one support and community outreach.

In this report, we celebrate our organization’s achievements as well as patients’ milestones—each with a unique journey toward accessing treatment and care.

We’re thrilled to share with you the significance of our growth into new frontiers, and the impact it’s had on the patients we support worldwide. We hope you see yourself in each of our achievements and feel how your support directly contributes to the lives of patients and families who are now able to face their cancer with dignity and hope.

Read the 2019 Annual Report

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….

  • My PCR Releases New Resource on Treatment Free Remission (TFR)

    My PCR Releases New Resource on Treatment Free Remission (TFR)

    My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).

  • Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity